meta:
  schema_version: '1.0'
  compatible_engine: cellswarm>=2.0
  calibrated_from: GSE169246 (Zhang et al. 2021) + GDSC2
  calibration_date: '2026-02-13'
combination_id: atezo_nabpaclitaxel
components:
- atezolizumab
- nab_paclitaxel
clinical_trial: IMpassion130
indication: TNBC
interaction_model: bliss_independence
synergy_rules:
  CD8_T:
    synergy_factor: 1.25
    affected_parameters:
    - activation
    - exhaustion
    notes: Nab-paclitaxel ICD + PD-L1 blockade
  Tumor:
    synergy_factor: 1.2
    affected_parameters:
    - apoptosis_susceptibility
    - immune_evasion
  Treg:
    synergy_factor: 1.1
    affected_parameters:
    - suppressive_activity
  Macrophage:
    synergy_factor: 1.15
    affected_parameters:
    - polarization
    - phagocytic_activity
  NK:
    synergy_factor: 1.1
    affected_parameters:
    - activation
  B_cell:
    synergy_factor: 1.0
    affected_parameters: []
toxicity_interaction:
  irAE_probability: 0.28
  dose_adjustment: 0.85
cancer_specific_modifiers:
  TNBC:
    efficacy_modifier: 1.15
    notes: IMpassion130 PD-L1+ IC>=1% PFS benefit
  Melanoma:
    efficacy_modifier: 0.7
    notes: Not standard
  NSCLC:
    efficacy_modifier: 0.8
    notes: IMpower150 uses different backbone
  CRC-MSI-H:
    efficacy_modifier: 0.6
    notes: ICI preferred alone
  CRC-MSS:
    efficacy_modifier: 0.3
    notes: Limited benefit
  Ovarian:
    efficacy_modifier: 0.5
    notes: Investigational
references:
- description: 'IMpassion130: Atezo+nab-paclitaxel in TNBC. Schmid et al. NEJM 2018'
  pmid: '30345906'
  verified: true
clinical_validation:
  source: GSE169246
  n_patients: 22
  pre_post_cell_changes:
    Tumor:
      fold_change: 1.1651
      direction: increase
    CD8_T:
      fold_change: 0.9677
      direction: decrease
    Treg:
      fold_change: 0.87
      direction: decrease
    Macrophage:
      fold_change: 0.9269
      direction: decrease
    NK:
      fold_change: 1.2805
      direction: increase
    B_cell:
      fold_change: 0.7024
      direction: decrease
